We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States.
- Recent PTCT Stock Price: $24.28
- Yearly Gain for PTCT stock: -50.61%
- Market Cap for PTCT stock: $1.98B
- P/E Ratio for PTCT stock: -3.117
Will PTCT's stock price go up? Is there an accurate PTCT stock forecast available?
TipRanks.com reports that PTC Therapeutics currently has 5 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $37.60. The target pricing ranges from a high PTCT forecast of $56 down to a low forecast of $26. PTC Therapeutics (PTCT)’s last closing stock price was $24.28 which would put the average price target at 64.74% upside.
In addition, TradingView issued a Strong sell rating for PTCT stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on PTCT stock.
Other analysts covering PTCT include:
- Robyn Karnauskas of Truist Financial issued a Buy rating with the price target of $45 on 22 hours ago
- Kelly Shi of Jefferies issued a Buy rating with the price target of $56 on 22 hours ago
- Joseph Schwartz of SVB Securities issued a Hold rating with the price target of $30 on 22 hours ago
- Gena Wang of Barclays issued a Hold rating with the price target of $26 on 1 day ago
If you are wondering if PTCT is a good stock to buy, here are 3rd party ratings for PTCT stock:
- TipRanks.com: Hold
- TradingView.com: Strong sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 40% (100 out of 252)
What is the sentiment on the street regarding PTC Therapeutics? (Current ratings compiled by TipRanks.com)
- News Sentiment for PTCT stock: Bearish
- Blogger Consensus for PTCT stock: Bullish
- Media Buzz for PTCT stock: High
- Insider Signal for PTCT stock: Negative
- Investor Sentiment for PTCT stock: ―
- Hedge Fund signal for PTCT stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on PTCT stock including scouring the social networks like PTCT StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for PTCT stock chart >>
Summary: Alnylam Pharmaceuticals Inc. is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference. The company's pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic areas - genetic medicines, cardio-metabolic disease and hepatic infectious disease. The company's lead drug-Onpattro received regulatory approvals in the United States and Europe for the treatment of hereditary transthyretin-mediated amyloidosis in adults. The FDA approved Givlaari for acute hepatic porphyria. The FDA approved Oxlumo injection for subcutaneous use, for the treatment of primary hyperoxaluria type 1 to lower urinary oxalate levels in pediatric and adult patients. Moreover, the company is evaluating inclisiran for hypercholesterolemia in partnership with The Medicines Company acquired by Novartis. The FDA approved Leqvio to reduce low-density lipoprotein cholesterol with two doses a year..
- Recent ALNY Stock Price: $179.77
- Yearly Gain for ALNY stock: -14.36%
- Market Cap for ALNY stock: $23.12B
- P/E Ratio for ALNY stock: -21.453
Will ALNY's stock price go up? Is there an accurate ALNY stock forecast available?
TipRanks.com reports that Alnylam Pharma currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $282.00. The target pricing ranges from a high ALNY forecast of $405 down to a low forecast of $236. Alnylam Pharma (ALNY)’s last closing stock price was $179.77 which would put the average price target at 41.36% upside.
In addition, TradingView issued a Strong sell rating for ALNY stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ALNY stock.
Other analysts covering ALNY include:
- David Lebovitz of Citi issued a Buy rating with the price target of $266 on 3 days ago
- Gena Wang of Barclays issued a Buy rating with the price target of $236 on 4 days ago
- Edward Tenthoff of Piper Sandler issued a Buy rating with the price target of $253 on 4 days ago
- Keay Nakae of Chardan Capital issued a Buy rating with the price target of $250 on 4 days ago
If you are wondering if ALNY is a good stock to buy, here are 3rd party ratings for ALNY stock:
- TipRanks.com: Strong Buy
- TradingView.com: Strong sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 37% (94 out of 252)
What is the sentiment on the street regarding Alnylam Pharma? (Current ratings compiled by TipRanks.com)
- News Sentiment for ALNY stock: Very Bullish
- Blogger Consensus for ALNY stock: Bullish
- Media Buzz for ALNY stock: Very High
- Insider Signal for ALNY stock: Very Negative
- Investor Sentiment for ALNY stock: Positive
- Hedge Fund signal for ALNY stock: Negative
The stock market is extremely volatile, and you need to do your own research on ALNY stock including scouring the social networks like ALNY StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ALNY stock chart >>
Summary: BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for serious life-threatening medical conditions, mostly for children. The company's portfolio comprises seven marketed products namely, Aldurazyme, Naglazyme, Kuvan a rare genetic enzyme deficiency disorder), Vimizim , Brineura, Palynziq and Voxzogo. BioMarin has a collaboration agreement with Sanofi's subsidiary Genzyme for Aldurazyme. Genzyme is BioMarin's sole customer for Aldurazyme and is responsible for marketing and selling Aldurazyme to third parties.'The newest drug in BioMarin's portfolio, Voxzogo for treating achondroplasia, the most common form of dwarfism. BioMarin's biologics license application (BLA) for Roctavian/valoctocogene roxaparvovec (valrox), a gene therapy for severe hemophilia A, was given a complete response letter (CRL) by the FDA.
- Recent BMRN Stock Price: $88.60
- Yearly Gain for BMRN stock: 0.52%
- Market Cap for BMRN stock: $16.59B
- P/E Ratio for BMRN stock: 170.654
Will BMRN's stock price go up? Is there an accurate BMRN stock forecast available?
TipRanks.com reports that BioMarin Pharmaceutical currently has 5 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $102.80. The target pricing ranges from a high BMRN forecast of $96 down to a low forecast of $120. BioMarin Pharmaceutical (BMRN)’s last closing stock price was $88.60 which would put the average price target at 29.74% upside.
In addition, TradingView issued a sell rating for BMRN stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on BMRN stock.
Other analysts covering BMRN include:
- David Lebovitz of Citi issued a Hold rating with the price target of $96 on 3 days ago
- Andreas Argyrides of Wedbush issued a Hold rating with the price target of $78 on 4 days ago
- George Farmer of Scotiabank issued a Hold rating with the price target of $95 on 5 days ago
- Christopher Raymond of Piper Sandler issued a Buy rating with the price target of $125 on 5 days ago
If you are wondering if BMRN is a good stock to buy, here are 3rd party ratings for BMRN stock:
- TipRanks.com: Moderate Buy
- TradingView.com: sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 37% (94 out of 252)
What is the sentiment on the street regarding BioMarin Pharmaceutical? (Current ratings compiled by TipRanks.com)
- News Sentiment for BMRN stock: Very Bullish
- Blogger Consensus for BMRN stock: Bullish
- Media Buzz for BMRN stock: Medium
- Insider Signal for BMRN stock: Very Negative
- Investor Sentiment for BMRN stock: Very Negative
- Hedge Fund signal for BMRN stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on BMRN stock including scouring the social networks like BMRN StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for BMRN stock chart >>
Summary: Laboratory Corporation of America Holdings or LabCorp is a leading healthcare diagnostics company, providing comprehensive clinical laboratory services and end-to-end drug development support. The provide vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions.
- Recent LH Stock Price: $201.17
- Yearly Gain for LH stock: 6.32%
- Market Cap for LH stock: $17.87B
- P/E Ratio for LH stock: 21.777
Will LH's stock price go up? Is there an accurate LH stock forecast available?
TipRanks.com reports that Laboratory currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $242.40. The target pricing ranges from a high LH forecast of $257 down to a low forecast of $230. Laboratory (LH)’s last closing stock price was $201.17 which would put the average price target at 21.25% upside.
In addition, TradingView issued a sell rating for LH stock over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on LH stock.
Other analysts covering LH include:
- Kevin Caliendo of UBS issued a Buy rating with the price target of $250 on 22 hours ago
- Ann Hynes of Mizuho Securities issued a Buy rating with the price target of $257 on 3 days ago
- Derik De Bruin of Bank of America Securities issued a Buy rating with the price target of $238 on 4 days ago
- Patrick B Donnelly of Citi issued a Hold rating with the price target of $230 on 4 days ago
If you are wondering if LH is a good stock to buy, here are 3rd party ratings for LH stock:
- TipRanks.com: Strong Buy
- TradingView.com: sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Strong Sell, Top 44% (112 out of 252)
What is the sentiment on the street regarding Laboratory? (Current ratings compiled by TipRanks.com)
- News Sentiment for LH stock: Very Bullish
- Blogger Consensus for LH stock: Bullish
- Media Buzz for LH stock: Medium
- Insider Signal for LH stock: Negative
- Investor Sentiment for LH stock: Very Positive
- Hedge Fund signal for LH stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on LH stock including scouring the social networks like LH StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for LH stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
==============================================================================
